Purple Biotech Ltd
PPBTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. The $1.8M market capitalization puts PPBT squarely in micro-cap range for its industry. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Market Cap
$1.8M
Beta
-0.55
P/E (TTM)
—
P/E (Fwd)
-1.07
EPS (TTM)
$-48.09
EPS (Fwd)
$-1.01
ROE
-111.1%
ROA
-20.3%
Cash
$6.1M
Total Debt
$134,000
Free CF
-$4.9M
52W Change
-81.7%
Annual Financials
Cash vs Debt
Where PPBT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PPBT finished 56.28% below its 150-day moving average ($2.47) and 67.07% below its 200-day moving average ($3.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PPBT overbought or oversold?
At the October 20, 2026 close, PPBT's RSI(14) was 15.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $6.1M in cash comfortably exceeding the $134K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$4.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -111.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.55 suggests PPBT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PPBT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.